AstraZeneca Gets Approval for Drug Treating Hyperkalaemia
February 24 2017 - 7:17AM
Dow Jones News
LONDON--AstraZeneca PLC (AZN.LN) said Friday it got approval for
ZS-9, its drug against hyperkalaemia, from the committee for
medicinal products for human use of the European medicines
agency.
Hyperkalaemia is a condition characterized by high potassium
levels in the blood serum caused by cardiovascular, renal and
metabolic diseases.
Shares at 1245 GMT down 22 pence, or 0.5%, at 4578.5 pence
valuing the company at GBP57.93 billion.
-Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter
@OlgaCotaga
(END) Dow Jones Newswires
February 24, 2017 08:02 ET (13:02 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Sep 2024 to Oct 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Oct 2023 to Oct 2024